O23 Proliferation and apoptosis in multiple myeloma prognostic factors or kinetic parameters?
โ Scribed by J. Minarik; V. Scudla; M. Ordeltova; J. Bacovsky; M. Zemanova; T. Pika
- Book ID
- 104323055
- Publisher
- Elsevier Science
- Year
- 2007
- Tongue
- English
- Weight
- 47 KB
- Volume
- 21
- Category
- Article
- ISSN
- 0268-960X
No coin nor oath required. For personal study only.
โฆ Synopsis
note, in 19 patients, remission achieved by bortezomib-based therapy was consolidated by high-dose therapy followed by autologous stem cell transplantation. With a median follow-up time of 11 months (1 27 months), the median progression-free survival of our entire patient population is 13.8 month, while the median overall survival has not been reached yet. We conclude that in a real-life setting, such as the entire myeloma practice of our Department, impressive medium-term survival results may be achieved using bortezomib-based therapy.
๐ SIMILAR VOLUMES
Six pts had progressive disease, two pts died in infections (1. Candida tropicalis pneumonia caused fatal pulmonary bleeding on day +8; 2. in another case a multiorgan failure developed after Enterococcus sepsis on day +115). Follow up time is 28 months (1 78), 12/17 pts are in complete remission (C